Quetiapine in Pregnancy
Quetiapine can be used during pregnancy when clinically necessary, but requires enhanced metabolic monitoring due to dose-related risks of gestational diabetes, particularly at higher doses.
Safety Profile
The evidence regarding quetiapine use during pregnancy is reassuring for major structural malformations but raises important metabolic concerns:
Malformation Risk
Quetiapine does not appear to increase the risk of major congenital malformations. A comprehensive meta-analysis of 13,090 pregnancies exposed to quetiapine found a major malformation rate of 4.1%, which is comparable to background population rates 1. The National Pregnancy Registry data similarly showed no increased risk, with an odds ratio of 1.04 (95% CI 0.38-2.85) compared to controls 2. No specific patterns of malformations have been identified 2, 3.
Metabolic Complications
The primary concern with quetiapine during pregnancy is gestational diabetes mellitus (GDM), which shows a clear dose-response relationship. When grouped with other high-risk metabolic second-generation antipsychotics (olanzapine, clozapine), quetiapine was associated with an adjusted risk ratio of 1.8 (95% CI 1.3-2.4) for GDM compared to untreated pregnant women, even after controlling for BMI 4. Multiple high-quality studies have confirmed this dose-dependent metabolic risk 1.
Other Pregnancy Outcomes
Quetiapine exposure has been associated with:
- Increased postpartum bleeding in vaginal delivery (aOR 1.65; 95% CI 1.13-2.42) 5
- Prolonged neonatal hospitalization ≥5 days (aOR 1.54; 95% CI 1.10-2.15) 5
- Higher placental-to-birth weight ratio 5
- Infants large for gestational age (aRR 1.6; 95% CI 1.3-1.9) 4
Neonatal Effects
The FDA label warns that quetiapine may cause extrapyramidal and/or withdrawal symptoms in neonates, including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, and feeding disorder 6. These effects are typically transient but require neonatal monitoring.
Pharmacokinetic Considerations
Quetiapine plasma concentrations decline dramatically during pregnancy, potentially compromising therapeutic efficacy. PBPK modeling demonstrates that quetiapine AUC decreases by 8.7% in the first trimester, 35.0% in the second trimester, and 49.1% in the third trimester 7. By the third trimester, plasma concentrations fall below the therapeutic range (100 ng/mL) for most of the dosing interval 7. Another study confirmed a 76.2% reduction in plasma levels during the third trimester 8.
Dose adjustments are likely necessary: Women in late pregnancy may require at least 2.5 times their baseline dose to maintain therapeutic drug levels 7. This creates a clinical dilemma, as higher doses increase metabolic risks while lower doses risk maternal psychiatric decompensation.
Clinical Management Algorithm
Decision-Making Framework
- Assess severity of maternal psychiatric illness - Untreated severe mental illness poses significant risks to both mother and fetus
- Consider timing - If possible, avoid first trimester exposure when organogenesis occurs, though malformation risk appears low
- Evaluate alternatives - Consider whether other antipsychotics with less metabolic risk (e.g., paliperidone, ziprasidone) might be appropriate 3, though data are more limited
- Balance risks - Weigh the dose-dependent metabolic risks against the risk of maternal relapse
If Quetiapine is Used
Use the lowest effective dose to minimize metabolic complications 1. However, recognize that:
- Doses may need to increase as pregnancy progresses to maintain efficacy 7, 8
- Therapeutic drug monitoring should be considered, particularly in the second and third trimesters
Monitoring Requirements
Enhanced metabolic surveillance is essential:
- Baseline glucose screening before or early in pregnancy
- Serial glucose monitoring throughout pregnancy, with particular attention to GDM screening
- Weight and BMI tracking at each prenatal visit
- Blood pressure monitoring (standard prenatal care)
- Consider therapeutic drug monitoring if available, especially if clinical response diminishes
Delivery Planning
- Anticipate neonatal withdrawal symptoms - Coordinate with neonatology for observation
- Monitor for increased postpartum bleeding 5
- Standard obstetric indications should guide delivery method; cesarean section is not specifically indicated for quetiapine exposure
Breastfeeding Considerations
The FDA label notes that quetiapine may impair fertility due to increased prolactin levels, though effects are reversible 6. Limited data exist on quetiapine in breast milk, and decisions about breastfeeding should weigh maternal mental health needs against potential infant exposure.
Important Caveats
Confounding by indication is a major limitation in observational studies of antipsychotic use during pregnancy. Women requiring antipsychotics often have multiple risk factors including smoking, substance use, obesity, and use of other psychotropic medications 5. These factors independently increase pregnancy risks, making it difficult to isolate the specific effects of quetiapine.
The risk of untreated maternal psychiatric illness must be considered. Severe mental illness during pregnancy is associated with poor prenatal care, substance use, suicide risk, and adverse neonatal outcomes. For many women, continuing quetiapine represents the safer option compared to psychiatric decompensation.
Pregnancy Registry
Patients should be informed about the National Pregnancy Registry for Psychiatric Medications 6, 2. Enrollment helps expand the evidence base for reproductive safety of psychiatric medications.
Key Takeaway
Quetiapine is not a major teratogen, but metabolic monitoring is mandatory. The decision to use quetiapine during pregnancy should prioritize maternal mental health stability while implementing rigorous glucose surveillance and using the minimum effective dose. Dose adjustments will likely be needed as pregnancy progresses, creating a complex balance between efficacy and metabolic risk.